Why Does My Patient Have Erythrocytosis?

Mar 1, 2017 by in HEMATOLOGY Comments Off on Why Does My Patient Have Erythrocytosis?

Primary polycythemias are the result of intrinsic abnormalities of the hematopoietic progenitors that lead to constitutive overproduction of red cells accompanied by low erythropoietin (EPO) levels. Secondary polycythemias are caused…

read more

Why is My Patient Anemic?

Mar 1, 2017 by in HEMATOLOGY Comments Off on Why is My Patient Anemic?

Anemia is a decreased number of circulating red blood cells and is a common medical condition faced in clinical practice. Anemia is caused by loss of red blood cells, destruction…

read more

Why Does My Patient Have Thrombocytopenia?

Mar 1, 2017 by in HEMATOLOGY Comments Off on Why Does My Patient Have Thrombocytopenia?

Thrombocytopenia, usually defined as a platelet count of less than 150,000/μL, is a common reason for a hematology consult in both the inpatient and outpatient setting. In most patients, the…

read more

The Antifolates

Mar 1, 2017 by in HEMATOLOGY Comments Off on The Antifolates

This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance,…

read more

Targeting the Hedgehog Pathway

Mar 1, 2017 by in HEMATOLOGY Comments Off on Targeting the Hedgehog Pathway

The Hedgehog (Hh) pathway is a signaling cascade that is evolutionally highly conserved and plays an important role in embryonic pattern formation and stem cell response to tissue damage. Given…

read more

Antimitotic Inhibitors

Mar 1, 2017 by in HEMATOLOGY Comments Off on Antimitotic Inhibitors

Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its…

read more

Tyrosine Kinase Inhibitors in Lung Cancer

Mar 1, 2017 by in HEMATOLOGY Comments Off on Tyrosine Kinase Inhibitors in Lung Cancer

Identification of driver mutations in growth related protein kinases, especially tyrosine kinases, has led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung cancer….

read more

Targeting Angiogenesis in Gynecologic Cancers

Mar 1, 2017 by in HEMATOLOGY Comments Off on Targeting Angiogenesis in Gynecologic Cancers

Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to…

read more
Get Clinical Tree app for offline access